StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
5
Publishing Date
2022 - 03 - 07
1
2021 - 12 - 06
1
2021 - 08 - 11
1
2021 - 06 - 11
1
2021 - 04 - 23
1
Sector
Health technology
5
Manufacturing
2
Tags
Abbvie
77
Active
14
Aesthetic
22
Alliances
19
America
42
Antibody
17
Application
15
Approval
37
Atopic dermatitis
10
Biomidwest
43
Biotech-beach
10
Business
12
Cancer
53
Cd20
13
Chmp
10
Clinical-trials-phase-iii
26
Collaboration
23
Conference
32
Contract
13
Deadline
11
Dermatitis
14
Disease
65
Drug
75
Duobody
13
Earnings
22
Europe
16
Events
24
Expected
18
Eye
17
Fda
42
Financial
26
Financial results
12
Genetown
11
Global
113
Growing
24
Growth
174
Health
20
Leukemia
16
Market
383
Meeting
12
Migraine
23
N/a
783
Pharma
17
Pharmaceuticals
11
Phase 3
30
Positive
31
Reach
16
Report
97
Research
81
Results
80
Rinvoq
28
Risankizumab
14
Set
15
Skyrizi
16
Therapeutics
88
Therapy
40
Treatment
117
Trial
32
Ulcerative colitis
14
Year
12
Entities
Abbvie inc.
5
Agios pharmaceuticals, inc.
2
Amgen inc.
2
Astellas pharma inc
2
Cti biopharma corp.
2
Cyclacel pharmaceuticals, inc.
2
Glaxosmithkline plc
1
Immune pharmaceuticals inc
1
Jazz pharmaceuticals plc
2
Mei pharma, inc.
2
Novartis ag
3
Teva pharmaceutical industries ltd
1
Symbols
ABBV
5
ACLX
1
AFMD
1
AGIO
2
ALLO
1
ALPMF
3
ALPMY
3
ALXO
1
AMGN
2
APRE
1
APVO
3
ATNM
1
BLUE
1
BMY
2
CRIS
2
CTIC
2
CYCC
2
FMTX
1
GLAXF
1
GLYC
2
GSK
1
IMAB
1
IMGN
1
IMNPQ
1
JAZZ
4
JNJ
2
KRON
2
KURA
2
LLY
1
MBRX
2
MEIP
2
MGNX
1
MRKR
1
NTLA
4
NVS
6
NVSEF
5
RFL
5
SNDX
1
TAK
1
TCBP
2
TEVJF
1
VOR
3
Exchanges
Nasdaq
3
Nyse
5
Crawled Date
2022 - 03 - 07
1
2021 - 12 - 06
1
2021 - 08 - 11
1
2021 - 06 - 11
1
2021 - 04 - 23
1
Crawled Time
11:00
1
12:00
2
14:00
1
14:04
1
Source
www.biospace.com
1
www.fda.gov
1
www.prnewswire.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Myeloid leukemia
symbols :
ABBV
save search
Acute Myeloid Leukemia (AML) Treatment Market size in APAC to grow by USD 277.03 Million | Driven by high incidence of acute myeloid leukemia | Technavio
Published:
2022-03-07
(Crawled : 11:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
3.59%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
13.83%
|
O:
-0.26%
H:
0.0%
C:
0.0%
ALPMY
|
$9.47
-1.11%
520K
|
Manufacturing
|
-40.89%
|
O:
1.58%
H:
0.0%
C:
-0.87%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
10.38%
|
O:
-0.63%
H:
0.0%
C:
0.0%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
|
-1.0%
|
O:
-0.7%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
11.16%
|
O:
-0.01%
H:
0.0%
C:
0.0%
treatment
myeloid leukemia
leukemia
acute myeloid leukemia
aml
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2021-2026: Ballooning Elderly Population - The Vital Growth Driver for AML Therapeutics
Published:
2021-12-06
(Crawled : 12:00)
- prnewswire.com
ALPMF
|
$9.17
43.47%
16K
|
Health Technology
|
-37.7%
|
O:
-1.49%
H:
1.45%
C:
0.92%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
18.68%
|
O:
2.02%
H:
0.04%
C:
-0.89%
IMNPQ
|
$0.001
|
Manufacturing
|
0.0%
|
O:
50.0%
H:
0.0%
C:
-33.33%
ALPMY
|
$9.47
-1.11%
520K
|
Manufacturing
|
-40.2%
|
O:
-3.39%
H:
3.45%
C:
3.3%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
15.3%
|
O:
-0.57%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
40.2%
|
O:
1.57%
H:
0.0%
C:
0.0%
MEIP
|
$3.3
1.54%
1.52%
26K
|
Health Technology
|
21.25%
|
O:
-4.4%
H:
0.0%
C:
0.0%
JAZZ
|
$109.96
0.63%
0.63%
760K
|
Health Technology
|
-13.68%
|
O:
-2.16%
H:
0.0%
C:
0.0%
CYCC
|
$1.85
-5.38%
10K
|
Health Technology
|
-50.45%
|
O:
-5.93%
H:
0.0%
C:
0.0%
CTIC
|
$9.09
0.05%
11M
|
Health Technology
|
498.36%
|
O:
7.24%
H:
0.0%
C:
0.0%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
31.42%
|
O:
2.53%
H:
0.0%
C:
0.0%
AGIO
|
$29.52
0.31%
0.3%
750K
|
Health Technology
|
-18.42%
|
O:
-5.47%
H:
0.0%
C:
0.0%
myeloid leukemia
leukemia
therapeutics
growth
acute myeloid leukemia
aml
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976.2 Billion by 2026
Published:
2021-08-11
(Crawled : 12:00)
- prnewswire.com
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
0.88%
|
O:
0.51%
H:
0.13%
C:
-0.27%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
43.84%
|
O:
0.3%
H:
0.16%
C:
-1.25%
MEIP
|
$3.3
1.54%
1.52%
26K
|
Health Technology
|
21.25%
|
O:
0.37%
H:
0.36%
C:
0.0%
JAZZ
|
$109.96
0.63%
0.63%
760K
|
Health Technology
|
-25.95%
|
O:
-0.09%
H:
1.32%
C:
0.35%
CYCC
|
$1.85
-5.38%
10K
|
Health Technology
|
-68.31%
|
O:
-0.19%
H:
0.19%
C:
-0.76%
CTIC
|
$9.09
0.05%
11M
|
Health Technology
|
214.71%
|
O:
1.73%
H:
0.34%
C:
-7.14%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
16.22%
|
O:
0.52%
H:
0.38%
C:
-0.44%
AGIO
|
$29.52
0.31%
0.3%
750K
|
Health Technology
|
-33.75%
|
O:
0.07%
H:
1.52%
C:
-0.32%
myeloid leukemia
leukemia
acute myeloid leukemia
aml
FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Published:
2021-06-11
(Crawled : 14:04)
- fda.gov
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
42.09%
|
O:
0.0%
H:
0.1%
C:
-0.71%
fda
granted
approval
leukemia
myeloid leukemia
grant
acute myeloid leukemia
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Published:
2021-04-23
(Crawled : 14:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
50.08%
|
O:
-0.31%
H:
1.88%
C:
1.52%
myeloid leukemia
positive
therapy
leukemia
chmp
acute myeloid leukemia
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.